Tandem Diabetes Care (TNDM) Accounts Payables (2013 - 2026)

Tandem Diabetes Care has reported Accounts Payables for 14 years, with the latest figure at $59.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables changed 0.1% year-over-year to $59.9 million; the trailing twelve-month figure through Mar 2026 stood at $59.9 million (changed 0.1% YoY), and the FY2025 full-year result was $47.1 million, up 5.22% from the prior year.
• Accounts Payables for Q1 2026 stood at $59.9 million, up from $47.1 million in the prior quarter.
• The five-year high for Accounts Payables was $61.5 million in Q3 2022, with the low at $44.7 million in Q4 2024.
• Historically, Accounts Payables has averaged $51.8 million across 5 years, with a median of $49.6 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables jumped 128.12% — and 2023, when it decreased 25.01%.
• Tandem Diabetes Care's Accounts Payables stood at $55.7 million in 2022, then decreased by 11.02% to $49.6 million in 2023, then decreased by 9.79% to $44.7 million in 2024, then gained by 5.22% to $47.1 million in 2025, then increased by 27.18% to $59.9 million in 2026.
• The last three Accounts Payables figures came in at $59.9 million (Q1 2026), $47.1 million (Q4 2025), and $47.5 million (Q3 2025), per Business Quant data.